1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-PC is a phospholipid that contains stearic acid at the sn-1 position and 15(S)-HpETE at the sn-2 position. It is produced via oxidation of 1-stearoyl-2-arachidonoyl-sn-glycero-3-PC by 15-lipoxygenase (15-LO). 1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-PC is toxic to human umbilical vein endothelial cells (HUVECs) when used at a concentration of 100 μM.

1-Stearoyl-2-15(S)-HETE-sn-glycero-3-PC is a phospholipid that contains stearic acid at the sn-1 position and 15(S)-HETE at the sn-2 position. It is produced via oxidation of 1-stearoyl-2-arachidonoyl-sn-glycero-3-PC by 15-lipoxygenase (15-LO).

1-O-Hexadecyl-2-eicosapentaenoyl-sn-glycero-3-PC is a compound that results from the incorporation of eicosapentaenoic acid (EPA) into lyso-PAF C-16, a process demonstrated in neutrophils from monkeys and humans consuming a diet rich in fish oils. Furthermore, it functions as a precursor for PAF C-16 synthesis via the remodeling pathway.

1-Stearoyl-2-myristoyl-sn-glycero-3-PC is a useful organic compound for research related to life sciences. The catalog number is T64546 and the CAS number is 20664-02-2.

1-Palmitoyl-2-lauroyl-sn-glycero-3-PC (1,2-PLPC) is a phospholipid with palmitoyl (16:0) and lauryl (12:0) acyl chains at the sn-1 and sn-2 positions, respectively. This mixed-chain phosphatidylcholine aids in researching the role of chain-chain contact interactions in maintaining the structural stability of lipid membrane bilayers.

1-Palmitoyl-2-arachidonoyl-sn-glycero-3-PC (PAPC) is a phospholipid found in biological membranes, featuring palmitic acid (16:0) and arachidonic acid (20:4) at the sn-1 and sn-2 positions, respectively. PAPC undergoes oxidation in vivo, producing derivatives that play roles in chronic inflammation and vascular disease. Additionally, PAPC has been utilized in the investigation of oxidized phospholipid signaling mechanisms. Notably, PAPC levels are diminished in isolated human multiple myeloma cells.

2-Stearoyl-sn-glycero-3-phosphatidylcholine (2-Stearoyl-sn-glycero-3-PC) is a lysophospholipid characterized by the presence of stearic acid at the sn-2 position. This compound has been identified in the myocardium of rabbits.

1-Oleoyl-2-palmitoyl-sn-glycero-3-phosphatidylcholine (PC), originating from oleic acid, is utilized in the synthesis of liposomes [1].

1-Stearoyl-2-docosahexaenoyl-sn-glycero-3-PC is a phospholipid in biological membranes containing stearic acid and docosahexaenoic acid at the sn-1 and sn-2 positions, respectively. It has been used to study the organization and dynamics of lipid membranes. In the superoxide dismutase 1 mutant transgenic mouse model of amyotrophic lateral sclerosis (ALS) 1-Stearoyl-2-docosahexaenoyl-sn-glycero-3-PC levels decrease in the anterior horn of L5 in late stages of the disease.1-Stearoyl-2-docosahexaenoyl-sn-glycero-3-PC can be used to study biological membranes.

1-Palmitoyl-2-oleoyl-sn-glycero-3-PC (Palmitoyloleoylphosphatidylcholine) is a phospholipid ubiquitous in cell membranes, with compositions in the range 0-60 mol% cholesterol.

1-Palmitoyl-2-Linoleoyl-sn-glycero-3-phosphatidylcholine (PC) is a phospholipid characterized by the incorporation of palmitic (16:0) and linoleic (18:2) acids at the sn-1 and sn-2 positions, respectively. It is utilized in the creation of micelles, liposomes, and various artificial membranes, playing a significant role in research on lipid peroxidation.

1-Stearoyl-2-eicosapentaenoyl-sn-glycero-3-PC is a phospholipid comprising stearic acid and eicosapentaenoic acid at the sn-1 and sn-2 positions, respectively, identified in human red blood cells (RBCs).

1-O-Hexadecyl-2-arachidonoyl-sn-glycero-3-PC undergoes acylation through the action of CoA-independent transacylase, transforming lyso-PAF C-16 into this compound. It serves as the predominant precursor in the biosynthesis of PAF C-16 via the remodeling pathway.

1-1(Z)-Hexadecenyl-2-palmitoyl-sn-glycero-3-PC, a plasmalogen, appears in various rat tissues including the liver, heart, kidney, and both gluteus and soleus muscles, as well as visceral and subcutaneous adipose tissues. It serves in lipid bilayer synthesis to investigate how amphiphilic compounds, like lysophosphatidylcholine (1-palmitoyl-2-hydroxy-sn-glycero-3-PC) and lysoplasmenylcholine, influence membrane dynamics.

1-Stearoyl-2-Adrenoyl-sn-glycero-3-PC (PC(18:0/22:4)) acts as a cyclin-dependent kinase (CDK) inhibitor, promoting apoptosis and restricting the proliferation of various cancer cell lines [1].

1-Palmitoyl-2-13(S)-HpODE-sn-glycero-3-PC is a phospholipid featuring palmitic acid at the sn-1 position and 13(S)-HpODE at the sn-2 position.

6-(1-Hydroxypentyl)-4-methoxy-2H-pyran-2-one. PC is a useful organic compound for research related to life sciences and the catalog number is T130784.

1. Ginkgetin has anti-influenza virus and anti-fungal activities. 2. Ginkgetin has anti-inflammatory activity, can down-regulates COX-2 induction in vivo against skin inflammatory responses. 3. Ginkgetin is a good STAT3 inhibitor and may be a useful lead

TV 3279 is a novel ChE-MAI inhibitor , and the neuroprotective properties depend on their ability to induce the anti-apoptotic proteins PKC, Bcl-2, Bcl-x, and SOD, and to block the nuclear translocation of the pro-apoptotic enzyme glyceraldehyde phosphate dehydrogenase in PC-12 and neuroblastoma cells.

Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species which are cytotoxic and pro-atherogenic. Many of these substances were isolated and purified from oxLDL and identified as phosphatidylcholine species containing a fragmented, oxidized short-chain fatty acid remnant at the sn-2 position. PAz-PC is one of the predominant oxLDL species and may be one of the important structural determinants of oxLDL.

Oxidized low-density lipoprotien (oxLDL) particles contain low molecular weight species which are cytotoxic and pro-atherogenic. Many of these substances were recently isolated and purified from oxLDL, and identified as phosphatidylcholine species containing a fragmented, oxidized short-chain fatty acid remnant at the sn-2 position. 1-(Palmitoyl)-2-(5-oxovaleroyl)-phosphatidylcholine, or POV-PC, is one of the oxLDL species derived from 2-arachidonoyl or eicosapentanoyl phospholipids. POV-PC confers CD36 scavenger receptor binding affinity more potently than any hydroperoxy PC species, and may be one of the more important structural determinants of oxLDL. Treatment of cultured endothelial cells with POV-PC stimulates monocyte binding, stimulates intracellular cAMP production, and strongly inhibits the LPS-induced binding of neutrophils.

Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species which are cytotoxic and pro-atherogenic. Many of these substances were recently isolated and purified from oxLDL, and identified as phosphatidylcholine species containing a fragmented, oxidized short-chain fatty acid remnant at the sn-2 position. KDdiA-PC is one of the most potent CD36 ligands among the oxLDL species. KDdiA-PC confers CD-36 scavenger receptor binding affinity to LDL at a frequency of only two to three KDdiA-PC molecules/LDL particle, and may be one of the more important structural determinants of oxLDL.

EGFR/HER2/DHFR-IN-2 (Compound 4b) serves as an inhibitor for EGFR, HER2, and DHFR, with IC50 values of 0.248, 0.156, and 0.138 μM, respectively. It exhibits anticancer activity, displaying IC50 values of 9.14, 7.33, 14.18, 24.87, 20.07, and 6.16 μM in Hep G2, HeLa, HEp-2, HCT 116, PC-3, and MCF7 cancer cell lines, respectively. Additionally, EGFR/HER2/DHFR-IN-2 has been shown to reduce the growth of breast cancer tumors [1].

1,2-Dipalmitoyl-13C-sn-glycero-3-PC is intended for use as an internal standard for the quantification of 1,2-dipalmitoyl-sn-glycero-3-PC by GC- or LC-MS. 1,2-Dipalmitoyl-sn-glycero-3-PC (DPPC) is a zwitterionic glycerophospholipid commonly used in the formation of lipid monolayers, bilayers, and liposomes for use in a variety of applications.1,2,3,4 It has been used in the formation of proteoliposomes for implantation of γ-glutamyl transpeptidase into human erythrocyte membranes.3 Incorporation of glycosphingolipid antigens into DPPC-containing liposomes increases the immunogenicity of the antigens in mice.4 |1. Ege, C., and Lee, K.Y.C. Insertion of Alzheimer's Aβ40 peptide into lipid monolayers. Biophys. J. 87(3), 1732-1740 (2004).|2. Leekumjorn, S., and Sum, A.K. Molecular simulation study of structural and dynamic properties of mixed DPPC/DPPE bilayers. Biophys. J. 90(11), 3951-3965 (2006).|3. Kalra, V.K., Sikka, S.C., and Sethi, G.S. Transport of amino acids in γ-glutamyl transpeptidase-implanted human erythrocytes. J. Biol. Chem. 256(11), 5567-5571 (1981).|4. Uemura, A., Watarai, S., Iwasaki, T., et al. Induction of immune responses against glycosphingolipid antigens: Comparison of antibody responses in mice immunized with antigen associated with liposomes prepared from various phospholipids. J. Vet. Med. Sci. 67(12), 1197-1201 (2005).

Phytochelatin 2, a short plant peptide, serves as an essential metal-binding compound. Phytochelatins are a diverse group of plant compounds that play a crucial role in chelating metals, safeguarding against metal toxicity, and maintaining metal homeostasis.

1-Linoleoyl-2-hydroxy-sn-glycero-3-PC (LGPC) is a lysophospholipid containing linoleic acid at thesn-1 position that has been found in mouse heart, lung, liver, spleen, kidney, plasma, and serum.1Serum levels of LGPC decrease with increasing insulin resistance and dysglycemia in humans.2 1.Okudaira, M., Inoue, A., Shuto, A., et al.Separation and quantification of 2-acyl-1-lysophospholipids and 1-acyl-2-lysophospholipids in biological samples by LC-MS/MSJ. Lipid Res.55(10)2178-2192(2014) 2.Gall, W.E., Beebe, K., Lawton, K.A., et al.α-Hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic populationPLoS One5(5)e10883(2010)

Thioester analogs of glycerophospholipids, in combination with Ellman's reagent, are convenient colorimetric substrates for the measurement of phospholipase (PL) activity. Palmitoyl thio-PC is a chromogenic PLA2 substrate that contains a palmitoyl thioester at the sn-2 position of the glycerol backbone. Hydrolysis of the thioester by PLA2 yields a free thiol that reacts readily with DTNB (Ellman's reagent) giving a bright yellow product with an absorbance maximum at 412 nm. Palmitoyl thio-PC has been used to measure bee venom sPLA2 activity in a phospholipid:Triton X-100 mixed micelle system.

Phosphatidylcholine (PC) species are a common class of phospholipids that comprise the mammalian cell membrane. 1,2-Dioctanoyl PC is a synthetic analog of natural phosphatidylcholine species containing saturated C8:O fatty acids in the sn-1 and sn-2 positions of the glycerol backbone. It exhibits a critical micelle concentration (CMC) value of 0.25 mM at 27°C. 1,2-Dioctanoyl PC serves as an efficient substrate for phospholipase D (PLD) as well as sPLA2 isozymes from bovine pancreas and bee venom.

NF-κB-IN-2 inhibits canonical NF-κB signaling induced by TNF-α in PC-3 cells.

B-Raf IN 8 (compound 7g) is a potent inhibitor of B-Raf (IC 50 = 70.65 nM). B-Raf IN 8 shows antitumor activity which has IC 50 values of 9.78, 13.78, 18.52 and 29.85 μM against hepatocellular carcinoma (HEPG-2), colon carcinoma (HCT-116), mammary gland (MCF-7) and human prostate cancer (PC-3) cells [1].

Neuroinflammatory-IN-2 (compound 7i) is a potent anti-neuroinflammatory agent, capable of acting on MAO-B (IC50: 10.30 μM). Neuroinflammatory-IN-2 inhibits 96.33% of Aβ1-42 aggregation at 25 μM. Neuroinflammatory-IN-2 exhibits neuroprotective activity in H2O2-induced PC-12 cell injury. Neuroinflammatory-IN-2 can be used to study Alzheimer's disease.

PON-PC, an oxidized phospholipid with a 9-carbon fatty acyl chain ending in an aldehyde at the sn-2 position, arises from the oxidation of palmitoyl oleoyl phosphatidylcholine (POPC) or through interaction with ozone in pulmonary surfactant. It is found in oxidized LDL. At a 40 µM concentration, PON-PC diminishes the production of TNF-α, nitric oxide (NO), and NADP+ in primary mouse alveolar macrophages and lowers the bactericidal capability of RAW 264.7 cells. Additionally, levels of PON-PC increase in the bronchoalveolar lavage fluid (BALF) of mice exposed to cigarette smoke or in older mice.

Pyruvate Carboxylase-IN-2 is a natural analog of erianin. Pyruvate Carboxylase-IN-2 (compound 29) is a potent inhibitor of pyruvate carboxylase (PC). In cell lysate-based and cell-based PC activity assays, Pyruvate Carboxylase-IN-2 shows IC 50 s of 0.065 and 0.097 μM, respectively. Pyruvate Carboxylase-IN-2 mediates the anticancer effect in human hepatocellular carcinoma (HCC).

B-Raf IN 7 (compound 6a) is a potent inhibitor of B-Raf with an IC 50 of 110.23 nM. B-Raf IN 7 has antitumor activity against colon carcinoma cells(HCT-116), mammary gland cells(MCF-7), hepatocellular carcinoma cells(HEPG-2), human cervical carcinoma cells(Hela) and human prostate cancer cells(PC-3). The IC50 values are 7.50, 9.87, 10.57, 11.63 and 12.83 μM, respectively [1].

Oxidized low-density lipoprotien (oxLDL) particles contain low molecular weight species which are cytotoxic and pro-atherogenic. Many of these substances were recently isolated and purified from oxLDL, and identified as phosphatidylcholine species containing a fragmented, oxidized short-chain fatty acid remnant at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl) phosphatidylcholine, or KOdiA-PC, is one of the most potent CD36 ligands among the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle, and may be one of the more important structural determinants of oxLDL.

Flutamide-d7 is intended for use as an internal standard for the quantification of flutamide by GC- or LC-MS. Flutamide is an androgen receptor antagonist and prodrug form of 2-hydroxy flutamide. Flutamide is converted to 2-hydroxy flutamide by the cytochrome P450 (CYP) isoform CYP1A2 in human liver microsomes. It is cytotoxic to PC3 and LNCaP prostate cancer cells with IC50 values of 98.8 and 81.8 µM, respectively. Flutamide (50 mg/kg per day) reduces tumor growth in a PC-82 mouse xenograft model. Formulations containing flutamide have been used in the treatment of prostate cancer.

ASK120067 is a potent and orally active inhibitor of EGFRT790M (IC50:0.3 nM) with selectivity over EGFRWT (IC50:6.0 nM). ASK120067 is a third-generation EGFR-TKI for the research of non-small cell lung cancer (NSCLC)[1]. In the in vitro kinase assay ASK120067 potently inhibits the EGFR L858R/T790M and EGFR T790M resistant mutants with IC50 values of 0.3 nM and 0.5 nM, respectively, as well as the EGFRexon19del sensitizing mutant (IC50= 0.5 nM). The 50 of ASK120067 against wild-type EGFR (EGFRWT) is 6 nM[1].ASK120067 selectively inhibits the growth of EGFR-mutant cell lines and exhibits potent antiproliferative activity in the mutant EGFR NSCLC cells, with IC50 values of 12 nM, 6 nM and 2 nM against NCI-H1975 (T790M mutation), PC-9, and HCC827 cells (sensitizing mutations), respectively. However, it shows moderate or weak anti-growth activities in A431, LoVo and A549 cells (EGFRWT), with IC50 values ranging from 338 nM to 1541 nM[1].ASK120067 (0.1-100 nM) inhibits the phosphorylation of EGFR at Tyrosine residue 1068 and its downstream signaling proteins AKT and ERK in NCI-H1975 cells (EGFRL858R/T790M) even at low dosage (0.1-1 nM). Additionally, ASK120067 inhibits p-EGFR and p-Akt and p-erk in EGFR WT A431 cell until the concentration reaches 10 to 100 nM[1]. ASK120067 (oral gavage; 5-20 mg/kg; once daily; 21 days) results in significantly regressed tumor growth, with a tumor growth inhibition (TGI) rate of 85.7%, and administration of 10 mg/kg ASK120067 causes dramatic tumor shrinkage with a TGI rate of 99.3%, exhibiting a similar potency with Osimertinib[1]. [1]. Tao Zhang, et al. Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol Cancer. 2020 May 13;19(1):90.

1,2-Dipropionyl-sn-glycero-3-phosphocholine (PC) is a phospholipid characterized by the presence of propionic acid at its sn-1 and sn-2 positions. This compound has applications in the investigation of interactions between water and the phosphocholine headgroup in aqueous solutions.

Calpain Inhibitor-2 is a lipophilic calpain inhibitor, and they showed moderate to good anti-proliferative effects in vitro compared to melanoma cell lines (A-375 and B-16F1) and PC-3 prostate cancer cells. was able to inhibit the invasion of 80% of DU-145 cells.

Arachidonoyl Thio-PC is a substrate for many phospholipase A2s (PLA2s) including sPLA2, cPLA2, and iPLA2. Cleavage of the sn-2 fatty acid by PLA2 results in generation of a free thiol which reacts with chromogenic reagents such as DTNB (Ellman's reagent) and DTP to allow quantitation of PLA2 activity. Isozyme-specific cPLA2 activity can be measured by excluding or inhibiting sPLA2 and iPLA2 activities in the assay.

VEGFR-2-IN-32 (Comp 3a) is an inhibitor of VEGFR-2, exhibiting an inhibitory concentration (IC 50) of 8.93 nM, and demonstrates cytotoxic activity towards PC-3 cells with an IC 50 of 1.22 μM, indicating its potential utility in anti-prostate cancer research [1].

1,2-Dierucoyl-sn-glycero-3-PC is a phospholipid containing erucic acid at the sn-1 and sn-2 positions. It has been used in the study of lipid membranes and to determine the effect of long-chain phospholipids on the secondary structure of human islet amyloid polypeptide (hIAPP).

Diheptanoyl Thio-PC is a substrate for all phospholipase A2s (PLA2s) with the exception of cPLA2 and PAF-acetyl hydrolase (PAF-AH). Interaction of this compound with a PLA2 results in cleavage of the sn-2 fatty acid generating a free thiol on the lysophospholipid. This free thiol can be detected using chromogenic substrates such as DTNB (Ellman's reagent) and DTP.

MS-0022 is a SMO antagonist. MS-0022 showed effective Hh signaling pathway inhibition at the level of SMO in the low nM range, and Hh pathway inhibition downstream of Suppressor of fused (SUFU) in the low µM range. MS-0022 reduced growth in the tumor cell lines PANC-1, SUIT-2, PC-3 and FEMX in vitro. MS-0022 is a treatment led to a transient delay of tumor growth that correlated with a reduction of stromal Gli1 levels in SUIT-2 xenografts in vivo.